Meridia (sibutramine hydrochloride): Early Communication about an Ongoing Safety Review

FDA is reviewing preliminary data from a recent study suggesting
that patients using sibutramine have a higher number of
cardiovascular events (heart attack, stroke, resuscitated cardiac
arrest, or death) than patients using a placebo.